Dr. Falk is an Associate Professor of Neurology and Pharmacology. Dr. Falk's research focuses on cellular and rodent models to test novel therapies for Parkinson’s disease PD) treatment in three areas: 1) Novel pharmacological treatments for L-DOPA-induced dyskinesias, a major side effect of PD treatment. 2) Testing novel neuroprotective growth factor mediated) gene therapy approaches for PD. 3) Development of blood-brain barrier penetrant glycopeptide drug candidates for the treatment of PD. He is the author of over 25 peer-reviewed journal publications, with an h factor of 13, and over 90 peer-reviewed abstracts and conference presentations. Dr. Falk holds a patent on the use of PACAP glycopeptides for the treatment of neurodegenerative diseases. He is a member of the Society for Neuroscience and of the International Parkinson and Movement Disorder Society. Dr. Falk is on the Grant Review Committee of the Parkinson’s Foundation. He has also has reviewed for the Michael J. Fox Foundation for Parkinson's Research, the Parkinson’s UK Foundation, the American Parkinson's Disease Association, and the National Science Foundation.